TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT06664983 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

DRUG: TPC chemotherapy
DRUG: cadonilimab combined TPC chemotherapy

Sponsor

Sun Yat-sen University